ArticleBioengineered2022
Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.
Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- CSF1-CSF1R signaling mediates tumor cell-macrophage crosstalk and prognosis in ccRCC.Cancer gene therapy · 2026Article
- Identification and Validation of Prognostic Biomarker Signatures Associated with Overall Survival in Colorectal Cancer: Evidence from Bioinformatics Analysis and an in vivo Study.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Clinical significance and functional characterization of RRN3 in gastric cancer: insights from pan-cancer analysis and experimental validation.Frontiers in oncology · 2026Article
- SPP1 (osteopontin): a key regulator orchestrating cancer progression and non-cancerous pathologies - therapeutic opportunities and future directions.Frontiers in cell and developmental biology · 2026Review
- The cost of persistent alarm: temporal transcriptional reprogramming of macrophages from acute activation to chronic immune suppression by day 11.Frontiers in immunology · 2026Article
- Article
- Article
- Combined anti-SPP-1 and anti-CTLA-4 immunotherapy enhances anti-tumor efficacy in hepatocellular carcinoma via IL-6/STAT3 pathway modulation.Cytotechnology · 2025Article
- Impact of SPP1 and HMOX1 Genes in Glioma: Correlations With Oncolytic Virus Infection, Adverse Prognosis and Increased Cell Proliferation.Journal of cellular and molecular medicine · 2025Article
- Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment.Signal transduction and targeted therapy · 2025Article
- Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms.Nature communications · 2025Article
- Investigating the Role of Osteopontin (OPN) in the Progression of Breast, Prostate, Renal and Skin Cancers.Biomedicines · 2025Article
- SPP1 is a plasma biomarker associated with the dia gnosis and prediction of prognosis in sepsis.Scientific reports · 2024Article
- High-Throughput Transcriptomics Identifies Chemoresistance-Associated Gene Expression Signatures in Human Angiosarcoma.International journal of molecular sciences · 2024Article
- SPP1 promotes the polarization of M2 macrophages through the Jak2/Stat3 signaling pathway and accelerates the progression of idiopathic pulmonary fibrosis.International journal of molecular medicine · 2024Article
- Systematic assessment of long-read RNA-seq methods for transcript identification and quantification.Nature methods · 2024Article
- Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2024Review
- Revealing cell-cell communication pathways with their spatially coupled gene programs.Briefings in bioinformatics · 2024Article
- Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.BMC bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted phosphoprotein 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.